ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ELAN / financials
SMMT (40) RDY (64) BMRN (74) JAZZ (49) ⌘ Pro Terminal β†’

Elanco Animal Health Incorporated (ELAN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$24.57 +1.95% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $24.61

Elanco Animal Health Incorporated (ELAN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $12.04B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELAN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ELAN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Elanco Animal Health Incorporated (NYSE: ELAN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $24.57 (+1.95% 1D, market cap $12.04B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, ELAN ranks #357 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ELAN compare to SMMT and RDY in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELAN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 55.0%, and ROIC of -2.5%. By comparison, SMMT (Summit Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.84B) and RDY (Dr. Reddy's Laboratories Ltd) posts a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.79B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELAN?
β–Ό

Per ELAN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739104), Elanco Animal Health Incorporated generated $4.71B in revenue (+6.2% YoY), -$232.0M in net income, and $284.0M in free cash flow against $13.36B in total assets and $3.06B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $24.61 (+0.16%)🧬 Cannibal Buyback (-1.24% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 6% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (45/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510045
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D Β· Rk D-
Cash (9)Whales (9)SEC (10)Macro (5)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE-5.9% Base Target
$29 Bull$23 Base$18 Bear
πŸ“¬ FREE ELAN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ELAN)Realized 20D OHLCV Swing Band: Β±6.1%
Deterministic 5-Pillar Attribution (45/100 Composite)
πŸ” WHY ELAN SCORES 45/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (27% of score)

SEC Form 4 / 13F Thermometer: 60% Net Buy β€’ Cannibal Buyback (-1.24% YoY Shares)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 1.24 (DISTRESS RISK (<1.8)) β€’ Piotroski F-Score 7/9

β–Ό #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (63.3) create a -15 pt regime headwind

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
37
Grade E$23.54-3.6% Next Q
Q2 (-2Q)
40
Grade D$22.69+2.4% Next Q
Q3 (-1Q)
42
Grade D$23.24+5.7% Next Q
Current
45
Grade D$24.57-6.3% Hist 90D Ξ±
Trajectory: E (37) β†’ D (45)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ELAN Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ELAN currently carries a cautious 45/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.03) and Max Pain ($25.80) forces dealer call-delta covering toward $29.38.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELANβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œELAN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How ELAN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$284.0M (6% FCF Margin)
Revenue$4.71BGross Profit $2.59B (55%)Cost of Sales $2.12BOp Profit $0 (0%)OpEx (R&D/SG&A) $2.59BNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $4.42B
FY24
Rev $4.44B
FY25
Rev $4.71B
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$4.71B55%-5.8%-$232.0M$284.0M-2.4%
FY 2024$4.44B54.9%9%$338.0M$394.0M3.2%
FY 2023$4.42B55%-32.9%-$1.23B$72.2M-29.8%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELAN)

  • βœ“Walkthrough of ELAN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ELAN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.87%β–² ASCENDING CHANNEL
2026-11-04O $23.06H $24.57L $23.06C $24.57VOL 6.54M
RES: $30.69SUP: $21.82SMA50: $23.03SMA200: $23.77
$28.58$26.09$23.60$21.12$18.63RES $30.69SUP $21.82$24.572026-05-052026-06-222026-08-062026-09-222026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELAN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ELAN Butterfly Map β†’ + Track ELAN β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
13.5%/yr Implied 5Y Growth

vs. +6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ELAN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ELAN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELAN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELAN)

Health Care Rank #357 of 1015 βš”οΈ SMMT vs ELAN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ELAN vs. SMMT, RDY, BMRN, JAZZ)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Elanco Animal Health Incorporated (ELAN) ranks #357 by composite RQD confidence (45/100, grade D) and #91 by equity capitalization ($12.04B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and β€” gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with ELAN at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ELAN ACTIVE
Elanco Animal Health Incorporated
D 45/100 β€” 55.0% -2.5% +1.95% $12.04B Benchmark Subject
SMMT
Summit Therapeutics Inc.
D- 40/100 β€” β€” -35.0% +6.76% $11.84B /smmt-vs-elan β†’
RDY
Dr. Reddy's Laboratories Ltd
C 64/100 32.8x β€” 9.9% +1.20% $11.79B /rdy-vs-elan β†’
BMRN
BioMarin Pharmaceutical Inc.
B 74/100 31.9x 77.7% 6.0% -3.10% $11.12B /bmrn-vs-elan β†’
JAZZ
Jazz Pharmaceuticals plc (Ireland)
D 49/100 β€” β€” -4.7% +7.14% $13.92B /jazz-vs-elan β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001739104 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elanco Animal Health Incorporated (ELAN) reported GAAP revenue of $4.71B (+6.2% vs. FY2024 revenue of $4.44B , and +6.7% cumulative change since FY2023) , GAAP net income of -$232.0M, operating cash flow of $560.0M, and free cash flow of $284.0M (-27.9% YoY). On the balance sheet, ELAN closed FY2025 with $13.36B in total assets against $3.06B in total debt (Altman Z-Score: 1.24, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.71B -$232.0M $560.0M $284.0M $13.36B $3.06B
FY2024 (FY) 2024-12-31 $4.44B $338.0M $541.0M $394.0M $12.61B $4.28B
FY2023 (FY) 2023-12-31 $4.42B -$1.23B $271.0M $72.2M $6.39B $1.49B

3. ELAN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELAN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Elanco Animal Health Incorporated (NYSE: ELAN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $24.57 (+1.95% 1D, market cap $12.04B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, ELAN ranks #357 in composite RQD confidence.

How does ELAN compare to SMMT and RDY in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELAN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 55.0%, and ROIC of -2.5%. By comparison, SMMT (Summit Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.84B) and RDY (Dr. Reddy's Laboratories Ltd) posts a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.79B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ELAN?

Per ELAN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739104), Elanco Animal Health Incorporated generated $4.71B in revenue (+6.2% YoY), -$232.0M in net income, and $284.0M in free cash flow against $13.36B in total assets and $3.06B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ELAN trading relative to its 50-day, 200-day, and 52-week technical levels?

ELAN last traded at $24.57 (+1.95% on volume of 6,460,538 shares), positioning the stock +6.69% above its 50-day simple moving average ($23.03) and +3.37% above its 200-day simple moving average ($23.77). Across its 52-week range of $19.40 to $27.98, ELAN sits at the 60.3% percentile with a 14-day RSI of 63.3 (BULLISH MOMENTUM) and an implied next-earnings move of Β±6.1% ($23.07 to $26.07).

Direct Sub-Reports: ELAN RQD Cockpit ELAN 12M Forecast ELAN Earnings & Move ELAN Dividends & DRIP ELAN Insiders & 13F ELAN Whale Options ELAN Profit Sankey ELAN News & Why
ROARABLE RATING BRIEF β€’ RQD 45/100 (D) βœ“ SEC XBRL & RQD VERIFIED

ELAN β€” Elanco Animal Health Incorporated: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Elanco Animal Health Incorporated (ELAN) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $24.57 (+1.95% 1D, market capitalization $12.04B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -2.5%, gross margin of 55.0%, operating margin of -6.0%, and free cash flow yield of 2.45%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (10/20): Incorporates a 0.96x equity beta, Altman Z-Score of 1.24, Piotroski F-Score of 7/9, and Debt/Equity of 0.44x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Elanco Animal Health Incorporated is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The profile identifies the company as operating in animal health. The company carries a market capitalization of $11.6B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Elanco Animal Health Incorporated (ELAN) reported $4.71B in annual revenue (up from $4.44B in FY2024, +6.2% YoY) and -$232.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.42B revenue, -$1.23B net income) through FY2025, ELAN scaled operating cash flow to $560.0M and free cash flow to $284.0M, backed by $13.36B in total assets against $3.06B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 2.45% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $19.40 – $27.98 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation against -6.0% operating margins and a 0.96x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should note that the absence of mapped links is a data gap, not evidence of an absence of dependencies.

  • Key Question #1: Can ELAN sustain or expand its -6.0% operating margin and -2.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.71B and free cash flow of $284.0M, how will capital allocation balance growth reinvestment against $3.06B in total debt?
  • Key Question #3: How sensitive is ELAN's 20.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.96x)?

ELAN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Elanco Animal Health Incorporated (ELAN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ELAN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ELAN Bull vs. Bear Conversation Board β€” What's Your Call at $24.57?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELAN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ELAN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $29.06 (+26.0%)
πŸ“Œ Pinned Debate

Forward P/E of 20 and a Piotroski F-Score of 7/9 suggest the market expects and the balance sheet can support an earnings and cash-flow

Long ELAN at $23.06 targeting $29.06. Forward P/E of 20 and a Piotroski F-Score of 7/9 suggest the market expects and the balance sheet can support an earnings and cash-flow recovery from negative trailing results.. Institutional whale score is 9/20 and the risk/reward vs. the $19.40 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” ELAN's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER β€’ Valuation Discipline 🐻 BEARISH 🎯 Target: $19.60 (-15.0%)
Spot @ $23.06

Negative ROIC of -2.5%, an Altman Z of 1.24, and the lowest pillar score of 5/20 on macro regime fit point to weak economics and limite

Sitting on the sidelines or leaning short ELAN above $23.06. Negative ROIC of -2.5%, an Altman Z of 1.24, and the lowest pillar score of 5/20 on macro regime fit point to weak economics and limited sector tailwind.. Until Fundamental Cash Engine (9/20) and FCF yield (2.45%) inflect higher, upside is capped near $27.98.

LIVE TAPE